Drugs / LTR192G
LTR192G
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05961059 | Oct 2024 → May 2025 overdue | shigellosis | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05327426 | Apr 2022 → Oct 2023 | poliomyelitis | University of Vermont | Unknown | No outcome recorded |
| Phase 1 | NCT04826094 | Mar 2021 → Feb 2024 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03922061 | Mar → Jul 2019 | poliomyelitis | University of Vermont | Completed | No outcome recorded |
| Phase 1 | NCT03548064 | Mar 2019 → Dec 2020 | escherichia coli infection | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1 | NCT03404674 | Jan 2018 → Mar 2019 | diarrheal disease | PATH | Completed | No outcome recorded |
| Phase 1 | NCT01382095 | Jul 2011 → Aug 2012 | escherichia coli infection | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Phase 1 | NCT00090688 | Aug 2004 → ? | diarrheal disease | U.S. Army Medical Research and Development Command | Withdrawn | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT01739231 | Sep 2012 → Oct 2013 | diarrheal disease | PATH | Completed | Met primary |
| Phase 22 trials | ||||||
| Phase 2 | NCT06692907 | Mar 2025 → Apr 2026 | escherichia coli infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT01922856 | Sep 2013 → Feb 2016 | enteritis | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-05-21 | Scandinavian Biopharma AB | Results Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries scandinavianbiopharma.se ↗
Furthermore, 85 percent of subjects receiving the vaccine coadministered with low dose adjuvant showed significant immune responses to all vaccine components. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2013-05-21 | Scandinavian Biopharma AB | Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries scandinavianbiopharma.se ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTR192G | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01382095 ↗ |
| Known as | dmLT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03548064 ↗ |
| Known as | LT(R192G/L211A) | “LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat-labile enterotoxin that has been genetically modified by replacing the arginine at...” NCT03548064 ↗1“double mutant \[LT(R192G/L211A)\] Enterotoxigenic Escherichia coli heat labile toxin (dmLT)” NCT03922061 ↗ |
| Modality | Protein / enzyme biologic | “The purpose of the study is to determine if immunization with dscCfaE with or without a modified E. coli heat labile enterotoxin, LTR192G, is safe and immunogenic when...” NCT01382095 ↗ |
| Route | Oral | “subjects received three oral doses of ACE527 with mucosal adjuvant (dmLT)” NCT01739231 ↗ |